BTPC Stock Overview
Active Biotech AB (publ), a biotechnology company, engages in the research, development, and production of pharmaceutical products Sweden.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Active Biotech AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.038 |
| 52 Week High | kr0.13 |
| 52 Week Low | kr0.029 |
| Beta | 0.35 |
| 1 Month Change | 1.05% |
| 3 Month Change | -70.19% |
| 1 Year Change | -37.96% |
| 3 Year Change | -70.69% |
| 5 Year Change | -86.57% |
| Change since IPO | -99.85% |
Recent News & Updates
Recent updates
Shareholder Returns
| BTPC | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -5.4% | -4.9% | -1.5% |
| 1Y | -38.0% | -19.9% | 0.9% |
Return vs Industry: BTPC underperformed the German Biotechs industry which returned -19.4% over the past year.
Return vs Market: BTPC underperformed the German Market which returned -0.4% over the past year.
Price Volatility
| BTPC volatility | |
|---|---|
| BTPC Average Weekly Movement | 45.2% |
| Biotechs Industry Average Movement | 4.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: BTPC's share price has been volatile over the past 3 months.
Volatility Over Time: BTPC's weekly volatility has increased from 33% to 45% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1983 | 8 | Helen Tuvesson | www.activebiotech.com |
Active Biotech AB (publ), a biotechnology company, engages in the research, development, and production of pharmaceutical products Sweden. It is developing Tasquinimod, a small molecule immuno-modulator, which is in Phase Ib/IIa clinical trial to treat multiple myeloma; Laquinimod, an immunomodulator that is in phase I clinical trial for the treatment of inflammatory eye disorders, including uveitis; and Naptumomab, an anti-cancer immunotherapy, which is in phase Ib/II clinical trial to treat patients with advanced solid tumors. The company has a licensing agreement with NeoTX Therapeutics Ltd.
Active Biotech AB (publ) Fundamentals Summary
| BTPC fundamental statistics | |
|---|---|
| Market cap | €17.05m |
| Earnings (TTM) | -€3.92m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-4.3x
P/E RatioIs BTPC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BTPC income statement (TTM) | |
|---|---|
| Revenue | kr0 |
| Cost of Revenue | kr0 |
| Gross Profit | kr0 |
| Other Expenses | kr45.80m |
| Earnings | -kr45.80m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 08, 2024
| Earnings per share (EPS) | -0.13 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did BTPC perform over the long term?
See historical performance and comparison